Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Julia Fox reveals when her celibacy will end as she appears in see
Chinese premier stresses nurturing new drivers for high
Xi visits people in Tianjin ahead of Spring Festival
Freshman Jasen Oliver drives in 4 and Indiana holds off Purdue 8
China's top legislature to review draft amendment to Criminal Law targeting bribers
Kyle Larson is on the pole for the 3rd NASCAR Cup race in a row, this time in Texas
Chinese lawmakers deliberate work report of NPC Standing Committee
Vatican makes fresh overture to China, reaffirms that Catholic Church is no threat to sovereignty
Georgia Steel puts on a VERY busty display in low
Trump visits Minnesota after son Barron's Florida high school graduation
Book of Xi's discourses on Chinese modernization published in English, bilingual versions